Forum Talk Programmes

Exhibition – Scientific Theatre
Overview of forum talk programmes organised by industry partners in the scientific theatre within the exhibition. Additional talks reserved after the date of printing will be announced on-site.

Saturday, 23 May 2020

16:15 – 16:30
Merck
Switching between high-efficacy treatments: lessons from Cladribine Tablets
Van Wijmeersch, Bart, Hasselt, Belgium

16:30 – 16:45
GW Pharma
Cannabinoid science: understanding the landscape
Jones, Nick, Cambridge, United Kingdom
- Overview of the cannabinoid landscape
- The science behind cannabinoids
- The birth of cannabinoid medicines

Sunday, 24 May 2020

09:30 – 09:45
Merck
MS treatment decisions and family planning
Magyari, Melinda, Copenhagen, Denmark

09:45 – 10:00
AveXis
Gene therapy revolution: an overview for the neurologist.
Baranello, Giovanni, London, United Kingdom

16:15 – 16:30
Roche
Improving the clinical diagnosis of Alzheimer’s disease in the clinic through the use of biomarkers
Frisoni, Giovanni, Geneva, Switzerland
16:30 – 16:45
GW Pharma
Cannabinoid science: understanding the landscape
Jones, Nick, Cambridge, United Kingdom
- Overview of the cannabinoid landscape
- The science behind cannabinoids
- The birth of cannabinoid medicines

Monday, 25 May 2020
09:30 – 09:45
Merck
Cladribine Tablets RWE: effectiveness beyond the dosing period
Vermersch, Patrick, Lille, France

16:15 – 16:30
Medtronic
Chronic sensing in DBS: a new paradigm
Guehl, Dominique, Bordeaux, France

16:30 – 16:45
Natus
Normal Values for Electrodiagnostic Studies
Nandedkar, Sanjeev D, Hopewell Junction, United States
Satellite Symposia Programmes

Saturday, 23 May 2020

Novartis

12:15 – 13:15/ Room Oslo

Uncovering hidden progression in MS: Are we making the most of the patient-physician partnership?

Chairpersons:
McCrea, Jonathan, Dublin, Ireland

Agenda

• Changing the conversation: how can we open the patient dialogue to help identify progression earlier?
• More than meets the eye: the impact of silent progression in MS
• Preserving patient independence: the importance of early intervention at all stages of MS
• Live audience Q&A

Faculty (All faculty TBC, dependent on availability)

Chair: Jonathan McCrea (Dublin, Ireland)
General Neurologist: Joao Cerqueira (Braga, Portugal)
MS specialist: Ralf Gold (Bochum, Germany)
MS specialist: Robert Shin, United States of America
Patient/patient advocate: Aidan Larkin (Ireland)
Predict, Prevent, Conquer: Beyond Head Pain

Chairperson:
Tassorelli Cristina, Pavia, Italy

12:15 – 12:25
Chairperson Welcome and Introductions
Tassorelli Cristina, Pavia, Italy

12:25-12:40
A Current Understanding of the Onset and Efficacy of CGRP mAbs
Lantéri-Minet, Michel, Nice, France

12:40-12:55
CGRP mAbs Efficacy Measured Over Time: Weekly and Monthly Persistence
Holle-Lee, Dagny, Essen, Germany

12:55-13:10
The Impact of CGRP mAbs on Work, Family, and Social Life
Lucas, Christian, Lille, France

13:10-13:15
Panel Discussion, Questions and Answers
All faculty

Symposium Objectives:
Explore new data in CGRP mAbs
Identify elements of productivity and impact to patient
Recognize the ideal clinical approach based on real world evidence
Determine ways to bridge clinical trial data to clinical practice
GW Pharmaceuticals

12:15 – 13:15 / Room Lisbon

An evolving landscape in the treatment of Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS): the influence of age and patient care

Chairpersons:
Baulac, Michel, Paris, France

12:15–12:20
Welcome and introductions
Baulac, Michel, Paris, France

12:20–12:35
An overview of the causes, clinical presentation and diagnosis of DS and LGS
Baulac, Michel, Paris, France

12:35–12:50
Changing priorities and experiences: growing up with DS or LGS
Steinhoff, Bernhard, Kehl-Kork, Germany

12:50–13:05
Looking into the future: the changing landscape of treatment of DS and LGS in children and adult
Russo, Emilio, Catanzaro, Italy

13:05–13:15
Open Q&A and meeting close
Baulac, Michel, Paris, France

Educational/Learning objectives

- Educate on the underlying causes of Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS). Describe how these causes translate into early clinical presentations and lead to diagnosis
- Outline the challenges and changing considerations presented by a transition to adulthood in patients with DS and LGS
- Provide an overview of the clinical management of paediatric and adult patients with DS or LGS, including unmet needs and evolving strategies for patient care
- Discuss the considerations that may influence a re-evaluation of treatment strategy in patients with DS and LGS in childhood and adulthood
Roche

13:45 – 14:45 / Room Oslo

Spinal muscular atrophy: how treatment expectations are evolving across the disease spectrum

Chairpersons:
Vlodavets, Dmitry, Moscow, Russian Federation

13:45 – 13:48
Welcome and introduction
Vlodavets, Dmitry, Moscow, Russian Federation

How have treatment expectations evolved in spinal muscular atrophy
Vlodavets, Dmitry, Moscow, Russian Federation

13:55 – 14:15
Beyond motor function: A closer look into infants living with Type 1 spinal muscular atrophy
Baranello, Giovanni, London, United Kingdom
Coratti, Giorgia, Rome, Italy

14:15 – 14:35
Meaningful outcomes: A closer look into children and adults living with Type 2 and 3 spinal muscular atrophy
Vlodavets, Dmitry, Moscow, Russian Federation
Lilien, Charlotte, Oxford, United Kingdom

14:35 – 14:45
Q&A, Summary and symposium close
Vlodavets, Dmitry, Moscow, Russian Federation
Novartis

13:45 – 14:45 / Room Vienna

Maintaining migraine management during times of a global health crisis

Chairpersons:
Pozo-Rosich, Patricia, Barcelona, Spain

13:45 - 13:50
Short-term challenges and longer-term opportunities
Pozo-Rosich, Patricia, Barcelona, Spain

13:50 - 14:00
The burden of migraine and the need for continuous and consistent management
Proot, Pascal, Ghent, Belgium

14:00 - 14:10
Adapting to the current reality of migraine management in Europe
Gantenbein, Andreas, Bad Zurzach, Switzerland

14:10 - 14:25
Migraine prevention: Experience from the US and implications for the current crisis
Tepper, Stewart J, Lebanon, United States

14:25 – 14:40
What are patients with migraine asking? A practical discussion with the panel
All faculty

14:40 – 14:45
Ensuring a positive legacy for our patients
Pozo-Rosich, Patricia, Barcelona, Spain
Assessing disease activity for an accurate prognosis of patients with Multiple sclerosis

Chairpersons:
Brochet, Bruno, Bordeaux, France

13:45–13:55
Welcome and introduction
Brochet, Bruno, Bordeaux, France

13:55–14:10
Interpreting clinical data: differential diagnosis, application of McDonald criteria
Oreja-Guevara, Celia, Madrid, Spain

14:10–14:25
Interpreting Magnetic Resonance Imaging: application of McDonald criteria, risk stratification
Rocca, Mara, Milan, Italy

14:25–14:40
Interpreting Multiple Sclerosis signs and symptoms: cognition, depression, fatigue
Penner, Iris-Katharina, Düsseldorf, Germany

14:40–14:45
Summary and close
Brochet, Bruno, Bordeaux, France

Learning objectives:
To improve the current and future management of patients with MS through the optimisation of clinical diagnosis, interpretation of MRI and evaluation of signs and symptoms of MS
Sunday, 24 May 2020

Roche

12:15 – 13:15 / Room Oslo

How can we ensure MS patient care continues to advance through these challenging times?

Chairpersons:
Ziemssen, Tjalf, Dresden, Germany

12:15–12:20
Welcome and introductions
Ziemssen, Tjalf, Dresden, Germany

12:20–12:30
What are the challenges posed to patient care by COVID-19?
Chan, Andrew, Bern, Switzerland

12:30–12:50
How can we optimise treatment strategies to better meet patient needs?
Ziemssen, Tjalf, Dresden, Germany
Tintoré, Mar, Barcelona, Spain

12:50–13:00
What learnings can we apply to advance disease control in the future?
Brownlee, Wallace, London, United Kingdom

13:00–13:10
Audience question and answer
All Faculty

13:10–13:15
Wrap-up and close
Ziemssen, Tjalf, Dresden, Germany
Outcome measures in adults living with SMA: standardization vs personalization

Chairpersons:
Sansone, Valeria, Milan, Italy

12:15–12:20
Opening
Sansone, Valeria, Milan, Italy

12:20–12:40
Outcome measures in adults living with SMA: What are our challenges?
Ciafaloni, Emma, Rochester, United States

12:40–13:00
Patient reported and exploratory outcome measures in adults living with SMA: Where do we want to go?
Sansone, Valeria, Milan, Italy

13:00–13:15
Q&A
All faculty
12:15 – 13:15 / Room Lisbon

The early diagnosis of Alzheimer’s disease: delineating the cause of memory impairment

Chairpersons:
Frisoni, Giovanni, Geneva, Switzerland

12:15 – 12:20
Welcome and introduction to our patient: a case study for discussion
Frisoni, Giovanni, Geneva, Switzerland

12:20 – 12:35
Comprehensive cognitive assessment to facilitate an early diagnosis
Van der Flier, Wiesje, Amsterdam, The Netherlands

12:35 – 12:50
Evaluating pathological biomarkers to confirm a diagnosis
Schott. Jonathan, London, United Kingdom

12:50 – 13:00
Healthcare system readiness for a paradigm shift to the early diagnosis of Alzheimer’s Disease
Krolak-Salmon, Pierre, Lyon, France

13:00 – 13:10
Panel discussion and Q&A
All faculty
Panelliers:
Frisoni, Giovanni, Geneva, Switzerland
Krolak-Salmon, Pierre, Lyon, France
Schott. Jonathan, London, United Kingdom
Van der Flier, Wiesje, Amsterdam, The Netherlands

13:10 – 13:15
Summary and close
Frisoni, Giovanni, Geneva, Switzerland
BIAL

12:15 – 13:15 / Room Amsterdam

Moving from the periphery to the core of the matter – where does opicapone fit in Parkinson’s disease?

Chairperson:
Bloem, Bastiaan, Nijmegen, The Netherlands

Let’s move to the periphery

Poewe, Werner, Innsbruck, Austria

Opicapone’s latest insights

Ebersbach, Georg, Beelitz, Germany
Ready or Not? What can be done to prepare health care systems for the diagnosis, treatment and care of Alzheimer’s disease in a future with disease modifying therapies?

Chairpersons:
Barbarino, Paola, London, United Kingdom

13:45 – 13:50
Welcome, Introduction of the panel and agenda

Barbarino, Paola, London, United Kingdom

13:50 – 14:05
The global landscape for dementia policy and global dementia readiness

Barbarino, Paola, London, United Kingdom

14:05 – 14:35
Debate session: What are the most impactful changes to the health care system that can be made today, that could ensure clinicians are ready to manage patients who would benefit from a future DMT?

Moderator:
Barbarino, Paola, London, United Kingdom

Panelliers:
Krolak-Salmon, Pierre, Lyon, France
Gunhild, Waldemar, Copenhagen, Denmark

14:35 – 14:45
Q&A session, Summary and meeting close

All faculty
Teva

13:45 – 14:45 / Room Vienna

Anti-calcitonin gene-related peptide monoclonal antibodies and the evolving migraine prevention landscape

Chairpersons:
Ashina, Messoud, Copenhagen, Denmark

13:45 – 13:50
Welcome and introductions
Ashina, Messoud, Copenhagen, Denmark

13:50 – 14:00
The true cost of migraine in Europe: the patient experience
Lanteri-Minet, Michel, Nice, France

14:00 – 14:15
Migraine pathophysiology and new insights for targeted prevention
Van den Brink, Antoinette Maasen, Rotterdam, The Netherlands

14:15 – 14:35
Monitoring response to anti-calcitonin gene-related peptide therapy: which outcomes and how often?
Reuter, Uwe, Berlin, Germany

14:35 – 14:45
Panel discussion & closing remarks
Ashina, Messoud, Copenhagen, Denmark

Teaching Objectives:

- Raise awareness of the burden of migraine and its unmet needs
- Update neurologists on the state of research on calcitonin gene-related peptide signalling in migraine
- Communicate the latest clinical data on anti-calcitonin gene-related peptide monoclonal antibodies
Alexion

13:45 – 14:45 / Room Lisbon

Complement inhibition in neurological disease: can we prevent damage and regain control? Key findings from phase 3 studies

Chairpersons:
Palace, Jackie, Oxford, United Kingdom

13:45 – 13:50
Welcome and introductions

Palace, Jackie, Oxford, United Kingdom

13:50 – 14:00
Generalized myasthenia gravis and neuromyelitis optica spectrum disorder: setting the scene

Palace, Jackie, Oxford, United Kingdom

14:00 – 14:15
Can we regain control in generalized myasthenia gravis?

Stangel, Martin, Hannover, Germany

14:15 – 14:30
Can we prevent relapse in neuromyelitis optica spectrum disorder?

Marignier, Romain, Lyon, France

14:30 – 14:45
Panel discussion, interactive Q&A and close

All faculty
Biogen

13:45 – 14:45 / Room Amsterdam

MS Looking forward: Innovations for individualised patient care

Chairpersons:
Thouvenot, Eric, Saint-Gély-du-Fesc, France

13:45-13:50
Welcome and opening
Thouvenot, Eric, Saint-Gély-du-Fesc, France

13:50-14:05
Digital innovation to improve patient care
Tintoré, Mar, Barcelona, Spain

14:05-14:35
Innovative research to tailor treatment dosing
Meuth, Sven, Muenster, Germany

14:35-14:45
Q&A and closing
Thouvenot, Eric, Saint-Gély-du-Fesc, France
Pfizer

18:30 – 20:00 / Room Lisbon

Recognizing & Treating the Many Faces of ATTR Amyloidosis
An update from a neurologist’s perspective

Chairpersons:
Camdessanche, Jean-Philippe, Paris, France

18:30 – 18:35
Welcome and Overview
Camdessanche, Jean-Philippe, Paris, France
Obici, Laura, Pavia, Italy

18:35 – 18:55
What is Amyloidosis?
Obici, Laura, Pavia, Italy

18:55 – 19:15
How to Achieve Early Patient Identification and Diagnosis?
Camdessanche, Jean-Philippe, Paris, France

19:15 – 19:45
What are the Therapeutic Options for Patients
Galán, Lucía, Madrid, Spain

19:45 – 20:00
Q&A
Camdessanche, Jean-Philippe, Paris, France

Learning Objectives:

- Highlight the physiological role of transthyretin (TTR)
- Review the pathology and systemic nature of hATTR amyloidosis, emphasizing the multidisciplinary aspects
- Underscore the importance of early identification and the correct application of diagnostic tools
- Review the latest efficacy and safety data of currently approved treatments for hATTR amyloidosis
- Discuss the importance of a multidisciplinary approach to hATTR management and treatment
Drug resistant epilepsy: where are we today?

Chairpersons:
Perucca, Emilio, Pavia, Italy

Introduction and Clinical case 1
Perucca, Emilio, Pavia, Italy

Seizure freedom in patients with drug-resistant epilepsy: science or fiction?
Trinka, Eugen, Salzburg, Austria

Clinical case 2
Perucca, Emilio, Pavia, Italy

Optimizing polytherapy to achieve efficacy and safety balance
Toledo, Manuel, Barcelona, Spain

Clinical case 3
Perucca, Emilio, Pavia, Italy

Mortality risk in patients with drug-resistant epilepsy
Rheims, Sylvain, Lyon, France

LIVE panel discussion
all faculty

Learning Objectives:
- Review current outcomes for patients with drug-resistant epilepsy and evidence around the probability of achieving seizure freedom
- Summarize challenges in managing polytherapy in patients with epilepsy: drug to drug interactions, most common adverse events and how to manage them to achieve an adequate safety – efficacy balance
- Highlight the increased risk of mortality in patients with epilepsy and review the main causes
- Discuss current landscape in drug-resistance epilepsy
Monday, 25 May 2020

Abbvie

12:15 – 13:15 / Room Lisbon

Disputes and Debates: Perspectives on the Early Recognition of Advanced Parkinson’s Disease and Continuous Dopaminergic Stimulation Therapies

Chairpersons:
K Ray, Chaudhuri, London, United Kingdom

12:15-12:20
Welcome and Opening Remarks
K Ray, Chaudhuri, London, United Kingdom

12:20-12:45
Pro/Con debate: Are Patients with Advanced Parkinson’s Disease Identified Early Enough to Benefit from Non-Oral Therapies?
Per, Odin, Lund, Sweden
Tove, Henriksen, Copenhagen, Denmark

12:45-13:13
Pro/Con debate: Is Continuous Dopaminergic Stimulation a Standard of Care in Advanced Parkinson’s Disease? Advanced Parkinson’s Disease
Regina, Katzenschlager, Vienna, Austria
Zvezdan, Pirtosek, Ljubljana, Slovenia

13:13 – 13:15
Closing remarks
K Ray, Chaudhuri, London, United Kingdom
Merck

13:45 – 14:45 / Room Oslo
Is it time for a new approach in MS management?

Chairpersons:
Vermersch, Patrick, Lille, France

13:45 – 13:50
Welcome

Vermersch, Patrick, Lille, France

13:50 – 14:00
Family planning in multiple sclerosis

Overview of family planning in multiple sclerosis and update of options for patients with different levels of disease activity

Magyari, Melinda, Copenhagen, Denmark

14:00 – 14:20
Assessing the long-term risk of DMDs in multiple sclerosis

Long-term considerations with different DMDs over the lifetime of the patient

Duddy, Martin, Newcastle, United Kingdom

14:20 – 14:35
Managing multiple sclerosis in the real-world

Cladribine Tablets real-world experience, including managing patients in Year 2 and long-term considerations

Oreja-Guevara, Celia, Madrid, Spain

14:35 – 14:45
Closing remarks and chair-moderated Q&A

Vermersch, Patrick, Lille, France
Britannia

13:45 – 14:45 / Room Vienna

Your advice, their decision: Empowering patients to make informed choices

Chairpersons:
Henriksen, Tove, Copenhagen, Denmark

13:45 – 13:50
Welcome and introductions
Henriksen, Tove, Copenhagen, Denmark

13:50 – 14:05
Reading the signs – clinical pictures in PD
Van Laar, Teus, Groningen, The Netherlands

14:05 – 14:20
Device – aided therapies – developing strategies to optimize quality of life
Chaudhuri, Ray, London, United Kingdom

14:20 – 14:35
Apomorphine infusion in the real world – maximizing patient benefits
Vérin, Marc, Rennes, France

14:35 – 14:45
Panel discussion with audience Q&A
Henriksen, Tove, Copenhagen, Denmark

Faculty:
Henriksen, Tove, Copenhagen, Denmark
Van Laar, Teus, Groningen, The Netherlands
Chaudhuri, Ray, London, United Kingdom
Vérin, Marc, Rennes, France
AveXis

13:45 – 14:45 / Room Lisbon

Predict, Prevent, Repair: Gene therapy for motor neurone diseases

Chairpersons:
Servais, Laurent, Liège, Belgium

13:45 – 13:50
Welcome and introduction: The future of gene therapy for motor neurone diseases (MND)
Servais, Laurent, Liège, Belgium

13:50 – 14:00
PREDICT: Diagnostic challenges in assessing MND patients
Lagrue, Emmanuelle, Tours, France

14:00 – 14:15
PREVENT: Addressing the therapeutic window in MND
Servais, Laurent, Liège, Belgium

14:15 – 14:30
REPAIR: Gene therapy for MND
Baranello, Giovanni, London, England

14:30 – 14:40
Q&A
All faculty

14:40 – 14:45
Symposium close
Servais, Laurent, Liège, Belgium
3-Days Satellite Session Programme

Sanofi Genzyme
Delve into the unmet needs of neuroscience

Saturday, 23 May 2020
09:30 – 10:00 / Room Helsinki
Will the Real Multiple Sclerosis please stand up?
Giovannoni, Gavin, London, United Kingdom

Sunday, 24 May 2020
13:15 – 13:45 / Room Helsinki
A Brain-first perspective in Multiple Sclerosis
Würfel, Jens, Basel, Switzerland

Monday, 25 May 2020
13:15 – 13:45 / Room Helsinki
Brain penetrance: the new road to take?
Wallström, Erik, Boston, United States
What is personalised medicine in MS today?

**Sunday, 24 May 2020**
09:30 – 10:00 / Room Helsinki
Gathering core, clinical data sets: Magnetic Resonance Imaging, cognition, McDonald 2017 criteria and diagnosis
Hartung, Hans-Peter, Düsseldorf, Germany

Sunday, 24 May 2020
16:15 – 16:45 / Room Helsinki
Risk stratification: holistic evaluation of prognostic markers to assess risk of progression in patients with Multiple Sclerosis
Comi, Giancarlo, Milan, Italy

**Monday, 25 May 2020**
09:30 – 10:00 / Room Helsinki
Risk stratification: what can biomarkers tell us with regard to progression and long-term outcome risks?
Thouvenot, Eric, Saint-Gély-du-Fesc, france